共 8 条
- [1] COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate resistant prostate cancer ineligible for therapy with 177Lu-PSMA-617JOURNAL OF NUCLEAR MEDICINE, 2024, 65Nordquist, LukeLengyelova, EvaAlmaguel, FrankisMancini, BrandonSong, HongArmstrong, AndrewZurita, AmadoAnderson, MoniqueParker, MichelleMiller, RobertIagaru, Andrei
- [2] SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS346 - TPS346Lengyelova, EvaIagaru, AndreiMancini, Brandon RobertSong, HongOsman, MedhatJosephson, DavidAlmaguel, FrankisSaltzstein, DanielParker, MichelleMiller, Robert M.Shore, Neal D.
- [3] SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in PSMA-negative biochemical recurrent prostate cancer patientsJOURNAL OF NUCLEAR MEDICINE, 2024, 65Nordquist, LukeLengyelova, EvaIagaru, AndreiMancini, BrandonSong, HongOsman, MedhatJosephson, DavidAlmaguel, FrankisSaltzstein, DanielParker, MichelleMiller, RobertShore, Neal
- [4] SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS246 - TPS246Johnson, GeoffreyLengyelova, EvaNordquist, Luke T.Prasad, VikasAnderson, MoniqueGervasio, OthonParker, MichelleMiller, Robert M.Sartor, A. OliverTagawa, Scott T.
- [5] Treatment of metastatic castrate-resistant prostate cancer patient with two cycles of 67Cu-SAR-bisPSMA (8 GBq) leads to complete response (RECIST) and undetectable PSA level: A case reportEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S249Gervasio, O.Nordquist, L.
- [6] SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancerJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Johnson, GeoffreyLengyelova, EvaNordquist, LukePrasad, VikasAnderson, MoniqueGervasio, OthonParker, MichelleMiller, Robert M.Sartor, A. OliverTagawa, Scott T.
- [7] SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancerJOURNAL OF NUCLEAR MEDICINE, 2024, 65Johnson, GeoffreyLengyelova, EvaNordquist, LukePrasad, VikasAnderson, MoniqueGervasio, OthonParker, MichelleMiller, RobertSartor, OliverTagawa, Scott
- [8] A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67ANNALS OF ONCOLOGY, 2009, 20 (12) : 1971 - 1976Hahn, N. M.Zon, R. T.Yu, M.Ademuyiwa, F. O.Jones, T.Dugan, W.Whalen, C.Shanmugam, R.Skaar, T.Sweeney, C. J.